Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "XEN1101"


3 mentions found


There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."
Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema
Carnival — Shares added 1% after being upgraded to buy from hold by Melius Research . Crown Castle — The telecommunications stock jumped nearly 4% following an activist push for change at Crown Castle. Shares of Crown Castle are down 20% this year. Okta — Shares of the software company dropped 3% Monday after JMP Securities downgraded Okta to market perform. Teva Pharmaceuticals — U.S.-traded shares jumped 3% after an upgrade from UBS to buy from neutral.
Persons: Locker, Josh Weinstein, Melius, Okta, JMP, Albemarle —, Etsy, TD Cowen, , Alex Harring, Hakyung Kim, Sarah Min, Michelle Fox, Jesse Pound, Darla Mercado Organizations: Citi, Melius Research, Crown, Elliott Investment Management, Sunday, JMP Securities, Albemarle, Battery Tech, U.S, Teva Pharmaceuticals —, UBS, Xenon Pharmaceuticals, , Adobe Analytics Locations: Crown, Albemarle
Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs says. The stock, he said, could jump 58% from Tuesday's close, given the bank's price target, and offers investors "innovation and blockbuster potential in an overlooked neuro category." Those gains would come even after a solid 24% gain this year and near 8% gain this month." And Xenon has solid balance sheet, Choi said. "Although pricing power will likely be limited, we think [the drug's] differentiated profile ... combined with good launch execution portends blockbuster FOS sales in the mostly generic epilepsy category," Choi wrote.
Total: 3